

ASX Announcement

Race In-person Investor Briefing Invitation – Perth

1 July 2024 – Race Oncology Limited (“Race”) is pleased to invite shareholders and potential new investors in Perth to attend an in-person investor briefing, followed by a light morning tea on 11 July 2024.

Through the briefing, Chief Executive Officer, Dr Daniel Tillett and Executive Director, Dr Pete Smith will present on recent progress in bringing Race’s new formulation of bisantrene, RC220, to the clinic as a cardioprotective and anticancer treatment, and the many related approaching key milestones.

The presentation will be followed by a Q+A session and informal discussion.

Briefing details

- Date: Thursday 11 July 2024
- Time: 10:15am AWST for a 10:30am start and a 12:00pm finish
- Location: Esplanade Hotel Fremantle – Abrolhos Room
Cnr Marine Terrace and Essex Street
Fremantle, WA
(Parking options: self-parking is available at the DRIVO carpark at 11 Essex Street; or City of Fremantle parking, Esplanade Reserve, 56 Marine Terrace)
- Format: Morning tea and an investor briefing with live Q+A
- RSVP: By Monday 8 July to phillipa.thorn@irdepartment.com.au
Please advise any dietary requirements.

The Race team looks forward to seeing all those who can join us on the day.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race's lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 bisantrene as a low intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Daniel Tillett, CEO
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au